Renal cell carcinoma cells (RCC)

Renal cell carcinoma (RCC) cells are malignant epithelial cells originating from the renal tubules, representing the most common form of kidney cancer. These cells are characterized by distinct genetic alterations, most notably the loss of the von Hippel-Lindau (VHL) tumor suppressor gene in the clear cell subtype, which leads to the stabilization of hypoxia-inducible factors (HIF) and subsequent overproduction of vascular endothelial growth factor (VEGF) (Hsieh et al., 2017). This metabolic and signaling reprogramming drives intense angiogenesis and tumor growth within the renal parenchyma. In the context of pharmacology, RCC cells are not a single molecular target but rather a complex cellular environment containing multiple therapeutic targets such as VEGFR, mTOR, and PD-L1 (Choueiri & Motzer, 2017). Modern treatments focus on inhibiting these specific pathways to starve the tumor of its blood supply or to restore the host's immune response against the malignant cells. Understanding the heterogeneity of these cells is essential for the development of targeted therapies and the identification of predictive biomarkers for patient management (Linehan & Ricketts, 2019).

Other names

RCC cellsHypernephroma cellsRenal adenocarcinoma cellsGrawitz tumor cellsKidney cancer cells

Therapeutic agents do not target the RCC cell as a single entity; instead, they target specific molecular pathways within or on the surface of these cells. Tyrosine kinase inhibitors (TKIs) block VEGFR and PDGFR to inhibit angiogenesis; mTOR inhibitors disrupt cell growth and protein synthesis; and immune checkpoint inhibitors (anti-PD-1/PD-L1) prevent the cancer cells from deactivating cytotoxic T-cells (Choueiri & Motzer, 2017; National Cancer Institute, 2024).